Cargando…

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor and the standard of care therapy for non-small cell lung cancer patients harboring EGFR-activating mutations. However, even for patients treated with osimertinib, resistance inevitably occurs leading to disease progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosibaty, Zeinab, Brustugun, Odd Terje, Zwicky Eide, Inger Johanne, Tsakonas, Georgios, Grundberg, Oscar, De Petris, Luigi, McGowan, Marc, Hydbring, Per, Ekman, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317954/ https://www.ncbi.nlm.nih.gov/pubmed/35884490 http://dx.doi.org/10.3390/cancers14143430

Ejemplares similares

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
por: Alexeyenko, Andrey, et al.
Publicado: (2022)

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
por: Kaźmierczak, Dominika, et al.
Publicado: (2022)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
por: Dyrbekk, Anne Pernille Harlem, et al.
Publicado: (2023)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients
por: Hydbring, Per
Publicado: (2023)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Thrombospondin‐1 mediates Rho‐kinase inhibitor‐induced increase in outflow‐facility
por: Shan, Sze‐Wan, et al.
Publicado: (2021)

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Structural basis for VPS34 kinase activation by Rab1 and Rab5 on membranes
por: Tremel, Shirley, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

Rab GTPases as Physiological Substrates of LRRK2 Kinase
por: Seol, Wongi, et al.
Publicado: (2019)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases
por: Jurczyluk, Julie, et al.
Publicado: (2016)

Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

“Dicing and Splicing” Sphingosine Kinase and Relevance to Cancer
por: Haddadi, Nahal, et al.
Publicado: (2017)

Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study
por: Bugge, Christoffer, et al.
Publicado: (2021)

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics
por: Alto, Neal M., et al.
Publicado: (2002)

Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
por: Purlyte, Elena, et al.
Publicado: (2017)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

Construction of a Plasmodium falciparum Rab-interactome identifies CK1 and PKA as Rab-effector kinases in malaria parasites
por: Rached, Fathia Ben, et al.
Publicado: (2012)

Phosphorylation of Rab37 by protein kinase C alpha inhibits the exocytosis function and metastasis suppression activity of Rab37
por: Tzeng, Hong-Tai, et al.
Publicado: (2017)

High expression of Ras‐specific guanine nucleotide‐releasing factor 2 (RasGRF2) in lung adenocarcinoma is associated with tumor invasion and poor prognosis
por: Nakagawa, Tomoki, et al.
Publicado: (2021)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
por: Tsakonas, Georgios, et al.
Publicado: (2022)

RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits
por: Lara Ordónez, Antonio Jesús, et al.
Publicado: (2019)

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
por: Eide, Hanne A., et al.
Publicado: (2016)

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting
por: Skribek, Marcus, et al.
Publicado: (2020)

Rab23 contributes to the progression of colorectal cancer via protein kinase B and extracellular signal-regulated kinase signaling pathways
por: Zhao, Tongbi, et al.
Publicado: (2019)

Thrombospondins and synaptogenesis★
por: Wang, Bin, et al.
Publicado: (2012)

Role of thrombospondin-1 and thrombospondin-2 in cardiovascular diseases (Review)
por: Zhang, Kaijie, et al.
Publicado: (2020)

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells
por: Thirstrup, Kenneth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hqtbsfksqoqklealhnp9e6ghj0